Literature DB >> 8521821

Loss of p53 function through PAX-mediated transcriptional repression.

E T Stuart1, R Haffner, M Oren, P Gruss.   

Abstract

Direct interactions between the genes that regulate development and those which regulate the cell cycle would provide a mechanism by which numerous biological events could be better understood. We have identified a direct role for PAX5 in the control of p53 transcription. In primary human diffuse astrocytomas, PAX5 expression inversely correlated with p53 expression. The human p53 gene harbours a PAX binding site within its untranslated first exon that is conserved throughout evolution. PAX5 and its paralogues PAX2 and PAX8 are capable of inhibiting both the p53 promoter and transactivation of a p53-responsive reporter in cell culture. Mutation of the identified binding site eliminates PAX protein binding in vitro and renders the promoter inactive in cells. These data suggest that PAX proteins might regulate p53 expression during development and propose a novel alternative mechanism for tumour initiation or progression, by which loss of p53 function occurs at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521821      PMCID: PMC394679          DOI: 10.1002/j.1460-2075.1995.tb00251.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  53 in total

1.  A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation.

Authors:  A Barberis; K Widenhorn; L Vitelli; M Busslinger
Journal:  Genes Dev       Date:  1990-05       Impact factor: 11.361

2.  Characterization of the human p53 gene promoter.

Authors:  S P Tuck; L Crawford
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 3.  Mechanisms of tumor progression.

Authors:  P C Nowell
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

6.  Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis.

Authors:  B Adams; P Dörfler; A Aguzzi; Z Kozmik; P Urbánek; I Maurer-Fogy; M Busslinger
Journal:  Genes Dev       Date:  1992-09       Impact factor: 11.361

7.  Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1.

Authors:  D Reisman; M Greenberg; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

Authors:  T J McDonnell; N Deane; F M Platt; G Nunez; U Jaeger; J P McKearn; S J Korsmeyer
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

9.  p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.

Authors:  A Rogel; M Popliker; C G Webb; M Oren
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

10.  The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element.

Authors:  B Bienz-Tadmor; R Zakut-Houri; S Libresco; D Givol; M Oren
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  49 in total

Review 1.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  PTIP, a novel BRCT domain-containing protein interacts with Pax2 and is associated with active chromatin.

Authors:  M S Lechner; I Levitan; G R Dressler
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

3.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

4.  Differential binding of NF1 transcription factor to P53 gene promoter and its depletion in human breast tumours.

Authors:  B K Nayak; B R Das
Journal:  Mol Biol Rep       Date:  1999-12       Impact factor: 2.316

Review 5.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

6.  Short-term urinary flow impairment deregulates PAX2 and PCNA expression and cell survival in fetal sheep kidneys.

Authors:  R Attar; F Quinn; P J Winyard; P D Mouriquand; P Foxall; M A Hanson; A S Woolf
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

7.  Dual roles for Pax-6: a transcriptional repressor of lens fiber cell-specific beta-crystallin genes.

Authors:  M K Duncan; J I Haynes; A Cvekl; J Piatigorsky
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 8.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

9.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells.

Authors:  Peixiang Wang; Donald R Branch; Meenakshi Bali; Gilbert A Schultz; Paul E Goss; Tianru Jin
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.